Testing different dose levels of a new immunotherapy called CT-202 to assess its safety in people with nectin-4-positive triple-negative breast cancer, bowel cancer, or urothelial cancer.

Inclusion Criteria:

  • Participants with nectin-4-positive triple negative breast cancer, colorectal cancer, or urothelial cancer that have received standard therapies

  • Participants with measurable disease per RECIST 1.1

  • ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks

  • Participants have adequate organ function.

Exclusion Criteria:

  • History of severe skin toxicity

  • Uncontrolled significant active infection or any medical or other condition that in the opinion of the Investigator would preclude the participant's participation in the study.

  • Concurrent participation in another investigational clinical trial.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 

Please share the referral to Dr Andrew Hill at Tasman Health care if you think it is eligible.